1-20 of 25
Harriet M. Kluger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma

Thazin N. Aung, Jonathan Warrell, Sandra Martinez-Morilla, Niki Gavrielatou, Ioannis Vathiotis, Vesal Yaghoobi, Harriet M. Kluger, Mark Gerstein, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3520–3532.
https://doi.org/10.1158/1078-0432.CCR-23-3932
Published: 15 August 2024
View article titled, Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma
Open the PDF for Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez-Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas O. Iannotti, Frank J. Hsu, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 74–81.
https://doi.org/10.1158/1078-0432.CCR-23-0475
Published: 05 January 2024
View article titled, A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Open the PDF for A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu, Amanda Ralabate, Barbara Johnson, Neta Shanwetter Levit, Gail Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael Hurwitz, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4757–4767.
https://doi.org/10.1158/1078-0432.CCR-21-0903
Published: 01 September 2021
View article titled, A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Open the PDF for A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 in another window
Includes: Supplementary data
Journal Articles

Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry

Sandra Martinez-Morilla, Franz Villarroel-Espindola, Pok Fai Wong, Maria I. Toki, Thazin Nwe Aung, Vasiliki Pelekanou, Brian Bourke-Martin, Kurt A. Schalper, Harriet M. Kluger, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 1987–1996.
https://doi.org/10.1158/1078-0432.CCR-20-3340
Published: 01 April 2021
View article titled, Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
Open the PDF for Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry in another window
Includes: Supplementary data
Journal Articles

PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice

Iñaki Eguren-Santamaria, Miguel F. Sanmamed, Sarah B. Goldberg, Harriet M. Kluger, Miguel A. Idoate, Benjamin Y. Lu, Jesús Corral, Kurt A. Schalper, Roy S. Herbst, Ignacio Gil-Bazo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4186–4197.
https://doi.org/10.1158/1078-0432.CCR-20-0798
Published: 14 August 2020
View article titled, PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Open the PDF for PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice in another window
Journal Articles

Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

Prathamesh M. Kulkarni, Eric J. Robinson, Jaya Sarin Pradhan, Robyn D. Gartrell-Corrado, Bethany R. Rohr, Megan H. Trager, Larisa J. Geskin, Harriet M. Kluger, Pok Fai Wong, Balazs Acs, Emanuelle M. Rizk, Chen Yang, Manas Mondal, Michael R. Moore, Iman Osman, Robert Phelps, Basil A. Horst, Zhe S. Chen, Tammie Ferringer, David L. Rimm, Jing Wang, Yvonne M. Saenger
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1126–1134.
https://doi.org/10.1158/1078-0432.CCR-19-1495
Published: 01 March 2020
View article titled, Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death
Open the PDF for Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death in another window
Includes: Supplementary data
Journal Articles

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz-Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O'Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6061–6072.
https://doi.org/10.1158/1078-0432.CCR-18-3488
Published: 15 October 2019
View article titled, Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Open the PDF for Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab in another window
Includes: Supplementary data
Journal Articles

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling

Maria I. Toki, Christopher R. Merritt, Pok Fai Wong, James W. Smithy, Harriet M. Kluger, Konstantinos N. Syrigos, Giang T. Ong, Sarah E. Warren, Joseph M. Beechem, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5503–5512.
https://doi.org/10.1158/1078-0432.CCR-19-0104
Published: 13 September 2019
View article titled, High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling
Open the PDF for High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling in another window
Includes: Supplementary data
Journal Articles

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Pok Fai Wong, Wei Wei, James W. Smithy, Balazs Acs, Maria I. Toki, Kim R.M. Blenman, Daniel Zelterman, Harriet M. Kluger, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2442–2449.
https://doi.org/10.1158/1078-0432.CCR-18-2652
Published: 15 April 2019
View article titled, Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
Open the PDF for Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

Lucia B. Jilaveanu, Maneka Puligandla, Sarah A. Weiss, Xin Victoria Wang, Christopher Zito, Keith T. Flaherty, Marta Boeke, Veronique Neumeister, Robert L. Camp, Adebowale Adeniran, Michael Pins, Judith Manola, Robert S. DiPaola, Naomi B. Haas, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 217–223.
https://doi.org/10.1158/1078-0432.CCR-17-1555
Published: 02 January 2018
View article titled, Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805
Open the PDF for Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805 in another window
Includes: Supplementary data
Journal Articles

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors

Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen, Justine V. Cohen, Lucia B. Jilaveanu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4270–4279.
https://doi.org/10.1158/1078-0432.CCR-16-3146
Published: 01 August 2017
View article titled, PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Open the PDF for PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

Melissa A. Wilson, Fengmin Zhao, Sanika Khare, Jason Roszik, Scott E. Woodman, Kurt D'Andrea, Bradley Wubbenhorst, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Lynn M. Schuchter, Sandra J. Lee, Keith T. Flaherty, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 374–382.
https://doi.org/10.1158/1078-0432.CCR-15-1162
Published: 14 January 2016
View article titled, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Open the PDF for Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma in another window
Includes: Supplementary data
Journal Articles

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

Harriet M. Kluger, Christopher R. Zito, Meaghan L. Barr, Marina K. Baine, Veronica L.S. Chiang, Mario Sznol, David L. Rimm, Lieping Chen, Lucia B. Jilaveanu
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 3052–3060.
https://doi.org/10.1158/1078-0432.CCR-14-3073
Published: 30 June 2015
View article titled, Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
Open the PDF for Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites in another window
Includes: Supplementary data
Journal Articles

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

Lucia B. Jilaveanu, Fabio Parisi, Meaghan L. Barr, Christopher R. Zito, William Cruz-Munoz, Robert S. Kerbel, David L. Rimm, Marcus W. Bosenberg, Ruth Halaban, Yuval Kluger, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (9): 2138–2147.
https://doi.org/10.1158/1078-0432.CCR-14-0861
Published: 30 April 2015
View article titled, PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Open the PDF for PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis in another window
Includes: Supplementary data
Journal Articles

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

Melissa A. Wilson, Fengmin Zhao, Richard Letrero, Kurt D'Andrea, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Sandra J. Lee, Lynn M. Schuchter, Keith T. Flaherty, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3328–3337.
https://doi.org/10.1158/1078-0432.CCR-14-0093
Published: 12 June 2014
View article titled, Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Open the PDF for Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib in another window
Includes: Supplementary data
Journal Articles

Plasma Markers for Identifying Patients with Metastatic Melanoma

Harriet M. Kluger, Kathleen Hoyt, Antonella Bacchiocchi, Tina Mayer, Jonathan Kirsch, Yuval Kluger, Mario Sznol, Stephan Ariyan, Annette Molinaro, Ruth Halaban
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2417–2425.
https://doi.org/10.1158/1078-0432.CCR-10-2402
Published: 14 April 2011
View article titled, Plasma Markers for Identifying Patients with Metastatic Melanoma
Open the PDF for Plasma Markers for Identifying Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6029–6039.
https://doi.org/10.1158/1078-0432.CCR-10-1490
Published: 16 December 2010
View article titled, Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Open the PDF for Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma in another window
Includes: Supplementary data
Journal Articles

C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas

Lucia B. Jilaveanu, Christopher R. Zito, Saadia A. Aziz, Patricia J. Conrad, John C. Schmitz, Mario Sznol, Robert L. Camp, David L. Rimm, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5704–5713.
https://doi.org/10.1158/1078-0432.CCR-09-0198
Published: 14 September 2009
View article titled, C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas
Open the PDF for C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas in another window
Includes: Supplementary data
Journal Articles

Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma

Saadia A. Aziz, Michael Davies, Elah Pick, Christopher Zito, Lucia Jilaveanu, Robert L. Camp, David L. Rimm, Yuval Kluger, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3029–3036.
https://doi.org/10.1158/1078-0432.CCR-08-2768
Published: 30 April 2009
View article titled, Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma
Open the PDF for Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma in another window
Includes: Supplementary data
Journal Articles

Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib

Lucia Jilaveanu, Christopher Zito, Sandra J. Lee, Katherine L. Nathanson, Robert L. Camp, David L. Rimm, Keith T. Flaherty, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 1076–1085.
https://doi.org/10.1158/1078-0432.CCR-08-2280
Published: 02 February 2009
View article titled, Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Open the PDF for Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib in another window
Includes: Supplementary data